TLSI Key Statistics, Chart & Performance
The current stock price of TLSI is 6.87 USD. In the past month the price increased by 47.11%. In the past year, price increased by 50.66%.
TLSI Latest News, Press Relases and Analysis
TLSI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About TLSI
Company Profile
TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company is headquartered in Westminster, Colorado and currently employs 110 full-time employees. The company went IPO on 2020-12-18. The firm is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
Company Info
TRISALUS LIFE SCIENCES INC
6272 W. 91st Ave.
Westminster COLORADO US
Employees: 110
Phone: 14153368917
TRISALUS LIFE SCIENCES INC / TLSI FAQ
What does TLSI do?
TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company is headquartered in Westminster, Colorado and currently employs 110 full-time employees. The company went IPO on 2020-12-18. The firm is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
What is the current price of TLSI stock?
The current stock price of TLSI is 6.87 USD. The price increased by 6.18% in the last trading session.
Does TLSI stock pay dividends?
TLSI does not pay a dividend.
How is the ChartMill rating for TRISALUS LIFE SCIENCES INC?
TLSI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for TLSI stock?
TRISALUS LIFE SCIENCES INC (TLSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.31).
What is TRISALUS LIFE SCIENCES INC worth?
TRISALUS LIFE SCIENCES INC (TLSI) has a market capitalization of 343.23M USD. This makes TLSI a Small Cap stock.
TLSI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TLSI. When comparing the yearly performance of all stocks, TLSI is one of the better performing stocks in the market, outperforming 91.8% of all stocks.
TLSI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TLSI. Both the profitability and financial health of TLSI have multiple concerns.
TLSI Financial Highlights
Over the last trailing twelve months TLSI reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS increased by 47.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.73% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TLSI Forecast & Estimates
13 analysts have analysed TLSI and the average price target is 11.58 USD. This implies a price increase of 68.62% is expected in the next year compared to the current price of 6.87.
For the next year, analysts expect an EPS growth of 38.95% and a revenue growth 55% for TLSI